It has been recently revealed by the drug firms Novartis AG and AstraZeneca Plc that their drugs undergoing trial for late-stage development for curing hypertension and depression have failed to prove their authenticity in the studies. This has also given rise to rumors about what sort of effect this shall tend to have on their sales and profits in the time to come.

The firm was of the view that they have received disappointing results in the trials of two medicines, which could lead them to suffer a loss of about $381.5 million.

On the other hand, Switzerland firm Novartis also revealed that they had stopped conducting the trial for a heart drug, Tekturna, due to safety reasons. This might also tend to put a pressure on the sales and profits of the firm.

In another revelation made by the firm Sanofi from France, it was revealed that a drug under trial from their firm, Aubagio, which was meant to treat multiple sclerosis, had proved to be useless, in the trial.

“The bad results emerged at the same time, but Novartis has been at the top of the leader board for drug launches over the past decade, while AstraZeneca lies more toward the bottom”, revealed Gbola Amusa, from UBS AG from London.

This has led to a fall in the shares of AstraZeneca by 3.3% in their London trading, it being the worse in six weeks. The other major drug making companies also saw recent decline due to their failed drug tests. Novartis fell 0.9%, with Sanofi bearing the least damages so far.

It is essential that these firms now pull up their socks and put in more rigorous efforts for conducting the drug tests so that they can finally make some profit.